ful prospective, randomized study of drug treatment in a large number of patients has yet to be reported. The NIH registry was not designed to study the efficacy of anticoagulation, vasodilator administration, or transplantation. Clearly, we need novel and safe approaches to diagnosis, evaluation, and treatment of primary pulmonary hypertension.
One approach has been to seek ways to diagnose the disorder early. Experimental studies in animals2 and isolated vessels suggest that elevated pulmonary arterial pressure may promote and accelerate further vascular damage. If so, with early detection, strategies to reduce pulmonary arterial pressure may retard the progress of the disease and improve the patient's quality of life. Recent research has emphasized the familial nature of primary pulmonary hypertension.3 Methods should be developed to screen family members and thereby facilitate early diagnosis.
Inherent in the goal of establishing an early diagnosis is the concept that vasoconstriction is most likely to be prominent early in the disease and that the constrictive component can be identified and its magnitude estimated to serve as a guide for subsequent vasodilator treatment. The finding that acute administration of a vasodilator is more dangerous in patients with the highest pressures and resistances4 is consistent with such a concept. The dangers of vasodilator treatment have involved the use of relatively long-acting vasodilators, which by their nature are nonspecific. Thus, in patients with precariously low and relatively fixed cardiac outputs, high right atrial pressures, and high pulmonary arterial pressures, drugs that cause systemic but not pulmonary, vasodilation have led to life-threatening systemic hypotension and even death. 4 Therefore, in the absence of a drug that relaxes pulmonary but not systemic vascular smooth muscle, two strategies have arisen to evaluate pulmonary vasoreactivity without the threat of dangerous systemic hypotension. The first strategy accepts systemic hypotension as a risk but advocates the use of a drug of brief duration given intravenously, so that stopping the drug reverses the hypotension within seconds. A prime example of this strategy is the use of prostacyclin. It has been given successfully to 100 primary pulmonary hy- A second strategy is to give a substance with an even shorter duration of action so that it acts on the lung vessels but is destroyed before it reaches the systemic circulation. The early use of acetylcholine5 was such a strategy. Acetylcholine has not achieved widespread application, probably because of its potential to slow or even arrest the sinoauricular pacemaker should the drug reach the coronary arteries in sufficient concentration. The inhalation of nitric oxide has recently been shown in experimental animals to be another example of a substance rapidly destroyed before it reaches the systemic circulation, 6 and it has been used as a pulmonary vasodilator in patients with primary pulmonary hypertension.7 An article8 in the present issue of Circulation reports that adenosine also has properties that make it an attractive drug with which to test pulmonary vasoreactivity in persons with primary pulmonary hypertension.
The advantages of adenosine are that it is stable, inexpensive, easily available, and rapidly destroyed by adenosine deaminase in endothelial cells and erythrocytes. In the report of Morgan et a18 in this issue of Circulation, adenosine effectively lowered pulmonary artery pressure and resistance. Although it lowered systemic resistance, cardiac output increased, resulting in little decrease in systemic arterial pressure. Adenosine, nitric oxide, and prostacyclin also cause vasodilation without requiring the release of endothelial-dependent relaxing factor. In primary pulmonary hypertension, where the endothelium may be abnormal, this is a potential, although untested, advantage.
As with any drug given to patients with primary pulmonary hypertension, care must be taken with adenosine administration. Experience with adenosine in thallium scintigraphy indicates that firstand second-degree heart block occurred in 9.5% and 3.5% of 607 patients, respectively.9 Although the dosage used by Morgan et a18 (50 ,ug/kg/min) is less than that used in scintigraphy (140 ,ug/kg/min9) and less than that previously reported in primary pulmonary hypertension (as much as 500 gg/kg/minlQ), prolonged infusions are associated with increased incidence of side effects.
A particularly important question relates to the utility of showing the extent of vasoreactivity in primary pulmonary hypertensive patients.11 Suggestions that vasodilators may prolong life have come from retrospective and uncontrolled studies, as recently reviewed.12 Although the use of a vasodilator acutely can provide a snapshot indicating vasoreactivity, it does not address the virulence of the disease course and therefore may be an imperfect indicator of prognosis. Also, a literature review indicates that some studies fail to support a beneficial effect of chronic vasodilator treatment." Consequently, although a determination of the extent of vasoreactivity in primary pulmonary hypertension may provide prognostic information, it is not yet established to what extent chronic vasodilator therapy is of longterm benefit and whether acute vasodilator trials identify patients who might benefit.
However, concepts and practice are changing. Disease progress is being monitored not only by assessment of right heart function and measurement of pressure and resistance on serial catheterization but also by the extent to which there is absence or loss of pulmonary vasoreactivity.4,5,7,8,0,12,3 With the current availability of heart-lung and single-lung transplantation, such hemodynamic assessment is useful in providing guidelines for the timing of transplantation. Furthermore, continuous infusion of prostacyclin has indicated that long-term administration can lower pressure and resistance below values seen with acute administration. 13 The implication is that some of the elevated resistance that is considered to be "fixed" might be reversible. Whether adenosine will be useful in chronic treatment remains to be seen. However, with major changes in primary pulmonary hypertension regarding concept and practice, a safe and rapidly acting pulmonary vasodilator is a welcome addition to the physicians' armamentarium for this highly fatal disease.
